Loading...
XNAS
ATXS
Market cap738mUSD
Dec 05, Last price  
12.93USD
1D
-1.45%
1Q
71.94%
Jan 2017
-64.18%
IPO
-4.01%
Name

Astria Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ATXS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
97.55%
Rev. gr., 5y
%
Revenues
0k
00000500,0000000000
Net income
-94m
L+29.32%
-15,669-18,118,000-21,884,000-32,630,000-36,060,000-27,364,000-25,870,000-26,243,000-37,064,000-30,173,000-50,165,000-72,891,000-94,260,000
CFO
-81m
L+18.65%
-15,583-16,366,000-20,412,000-29,793,000-32,858,000-26,836,000-23,465,000-26,569,000-32,485,000-30,151,000-43,533,000-68,445,000-81,212,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
URL
https://astriatx.com/
IPO date
Jun 25, 2015
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT